dcb

DCB (3,3'-dichlorobenzaldazine) is an allosteric ligand for mGluR5 and shows the negative modulatory effect of 3,3′-dimethoxybenzaldazine (DMeOB). DCB blocks the positive allosteric regulation of mGluRs with the help of 3,3′-difluorobenzaldazine (DFB).

Z-Asp-CH2-DCB is an irreversible inhibitor of broad-spectrum caspases.

Tylophorine analog DCB-3503 is a potential anticancer and immunosuppressive agent. DCB-3503 suppresses the translation of cellular regulatory proteins, including cyclin D1, at the elongation step. DCB-3503 allosterically regulates the ATPase and chaperone activities of HSC70 by promoting ATP hydrolysis in the presence of specific RNA binding motifs (AUUUA) of cyclin D1 mRNA.

DCB29 is a selective inhibitor of the BPTF bromodomain with an IC50 value of 13.2 μM. It is utilized in research for treating diseases related to BPTF, such as bladder cancer, colorectal cancer, melanoma, leukemia, and other cancers.

L594881, also known as 3',4'-Dichlorobenzamil or DCB, is an inhibitor of Na+/Ca2+ exchanger, Na+ transport and sarcoplasmic reticulum Ca2+ release channels. L594881 can inhibit Na+/Ca2+ exchanger, Na+ transport and sarcoplasmic reticulum Ca2+ release channels.

DCBCI0901 is an inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity.

m-Chloro-DCBA is a bioactive chemical.

m-Fluoro-DCBA is a bioactive chemical

DCBA, an endogenous metabolite of the insect repellent N-N-diethyl-meta-toluamide (DEET), is utilized to evaluate DEET exposure through its concentration levels in urine.

dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.

DCBY02 represents a highly specialized humanized monoclonal antibody specifically engineered to target the human CD93 (C1qR1) receptor with exceptional binding affinity. It effectively facilitates the measurable normalization of tumor vasculature by blocking the interaction between CD93 and its ligands, such as IGFBP7 and MMRN2, across various preclinical experimental models to evaluate the reduction of intratumoral hypoxia and the enhancement of T-cell infiltration during strictly monitored laboratory observation periods and functional immuno-normalization assays to ensure high experimental sensitivity.

Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized monoclonal antibody targeting Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2/ESDN/CLCP1). DCBLD2 is a type I transmembrane protein overexpressed in various malignancies (e.g., lung adenocarcinoma, glioma) and acts as a signal relay for growth factor signaling like EGFR. FA19-1 specifically binds to the extracellular domain of DCBLD2, blocking its mediated signaling—such as AKT activation or cisplatin-induced EMT—thereby inhibiting tumor cell migration, invasion, and distant metastasis.

Anti-DCBLD2CLCP1 Antibody (FA19-1) is a human monoclonal antibody (mAb) specifically targeting DCBLD2.

Chlorthiamid is a herbicide.

DC-BPi-07 is a selective BPTF inhibitor with an IC50 value of 16.0 nM for BPTF-H4. It is applicable in research related to leukemia.

Dichlorobutadiene can be used in related research in the field of life sciences. Its product number is T31434 and CAS number is 28577-62-0.

DC-BPi-11, a potent inhibitor of the bromodomain PHD finger transcription factor (BPTF), exhibits significant anti-proliferative effects against leukemia cells with an IC50 value of 698 nM.

DC-BPi-03 is a potent BPTF-BRD inhibitor, exhibiting an IC50 of 698.3 nM and a Kd of 2.81 μM.

DC-BPi-11 hydrochloride is a BPTF (bromodomain PHD finger transcription factor) inhibitor with an IC50 value of 698 nM, demonstrating significant anti-proliferative effects on leukemia cells [1].

Nucleoside phosphonamidite;Fluoro-modified nucleosides;2'-Modified nucleosides

Tylophorine, (-)- is a biomedical.

OPC-167832 is a highly potent and orally bioavailable dprE1 inhibitor with an IC₅₀ of 0.258 μM. It exhibits anti-mycobacterial activity against Mycobacterium tuberculosis and can be used in tuberculosis-related research.